Bedrijfsoverzicht
Codexis, Inc. operates within the healthcare sector, specifically functioning in the biotechnology industry by providing technology solutions for therapeutics manufacturing. The company leverages its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes across a global footprint that includes the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, and New Zealand. This biotechnology firm employs a workforce of 146 individuals and holds a market capitalization of $203.55M with annualized revenue of $70.39M. These financial metrics indicate that the company operates as a mid-sized entity within the biotechnology landscape, possessing a substantial cash reserve relative to its revenue base but currently generating negative earnings. The valuation suggests the market places a significant premium on the company's intellectual property and technological capabilities despite the absence of current profitability.
Financiële gezondheid
The company reported a revenue of $70.39M over the trailing twelve months, yet it recorded a net income of -$43,974,000 and an EBITDA of -$33,084,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses heavily outweigh gross profits, a common characteristic in early-stage biotechnology firms focused on R&D. Free cash flow stands at -$5,074,125, which indicates that the company is currently consuming cash rather than generating it, implying limited financial flexibility without external capital injections. Despite negative profitability, the three reported margins provide specific insights: a gross margin of 12.4% shows the cost of goods sold relative to sales, an operating margin of 35.9% suggests efficient control over operating expenses before interest and taxes, and a profit margin of -62.5% highlights the deep losses relative to total revenue. On the balance sheet, the company holds $78.21M in cash against $73.21M in debt, resulting in a debt-to-equity ratio of 144.88, which signifies a highly leveraged position where debt exceeds equity. However, the current ratio of 3.82 indicates strong short-term liquidity, suggesting the company can comfortably meet its short-term obligations with its current assets. Return on Equity is -74.9% and Return on Assets is -16.1%, metrics that reveal that management is currently destroying shareholder value and utilizing assets to generate losses rather than returns.
Waarderingsbeoordeling
Valuation multiples for Codexis, Inc. reflect its unprofitable status, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -10.18. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a future trajectory where earnings must turn positive before traditional valuation metrics become applicable. The price-to-book ratio is 4.01, indicating that the market values the company at more than four times its book value, suggesting a significant premium placed on its intangible assets and technology platform. Alternative valuation metrics such as a price-to-sales ratio of 2.89 and an EV/EBITDA of -6.00 further illustrate that investors are focusing on revenue growth and asset backing rather than earnings power. The stock's price range over the past year fluctuated between a 52-week low of $0.96 and a 52-week high of $3.87. Without a specific current price provided in the facts, the range itself demonstrates a wide trading band, and the negative forward P/E suggests the market expects earnings recovery to justify the current share price relative to the historical high of $3.87. The beta value of 2.08 indicates that the stock's price volatility is more than double that of the broader market, reflecting the high risk profile associated with small-cap biotechnology stocks.
Growth & Income
Revenue growth year-over-year stands at 81.3%, while earnings growth is N/A due to the company's current loss position. The absence of earnings growth data combined with robust revenue expansion implies that the company is scaling its top line faster than its bottom line can improve, which is typical for companies in the research and development phase. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders but instead reinvests all available capital into growth initiatives, R&D, and operations. This reinvestment strategy prioritizes long-term technological advancement and market expansion over providing immediate income returns to investors. The overall growth and income profile is characterized by aggressive revenue expansion supported by a highly leveraged balance sheet and a lack of current profitability or dividend distributions.